Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

Abstract

Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thromboembolism.

Haematologic Parameters in Metastatic Colorectal Cancer Patients Treated with Capecitabine Combination Therapy

“…However, after three cycles of treatment, PCT and PLT values were higher in patients receiving Bevacizumab, which has been reported to be associated with delayed wound healing, gastrointestinal perforation, hemorrahage, venous and arterial thromboembolism, hypertension and proteinuria (Gordon et al, 2005). In addition, arterial thrombosis has been observed to be increased in patients with metastatic colon cancer using Bevacizumab (Scappaticci et al, 2007). Similarly, our study showed a higher incidence of thrombosis in patients receiving Bevacizumab (7 vs 4 pts) (p=0.07).…”

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

“…Several adverse events have been reported with the systemic administration of anti-VEGF monoclonal antibodies, including thromboembolic events, myocardial infarction, stroke, hypertension, gastrointestinal perforations, and kidney disease. 25,[41][42][43] As all of the intravitreal anti-VEGF agents have been reported to be associated with detectable levels in the systemic circulation that may significantly suppress systemic VEGF levels, there is a scientific rationale for the occurrence of potential systemic adverse events. 43 Large-scale clinical trials have demonstrated that pegaptanib has an excellent safety profile, with no systemic adverse effects attributable to VEGF inhibition.…”

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

“…The use of bevacizumab was associated with a 3.1% risk for severe bleeding (versus 2.5% for placebo) and a 1.5% rate of gastrointestinal perforation (versus none for placebo). Other grade Ն3 toxicities attributed to bevacizumab included arterial thromboembolic events (2% versus 1%), wound-healing complications (1.3% versus 0.5), and proteinuria (any proteinuria, 26% versus 21%, but no difference in grade 2 or 3 proteinuria) [1,65,66]. The incidence rates of adverse events were similar in the NO16966 clinical trial (Table 4 and Fig.…”